All In Biotech

Drug Trial Radar · NCT00709852

Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging

A Multicenter, Randomized, Double-blind, Crossover, Phase 3 Study to Determine the Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients Referred for Contrast-enhanced MRI of the Central Nervous System (CNS)

Last checked: Nov 19, 2026Latest source record: Dec 30, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 402 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

402

Actual

Start

Jun 2008

Primary completion

Apr 2009

Study completion Apr 2009

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Jul 3, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study involves the use of Magnetic Resonance Imaging (MRI) contrast agents called gadobutrol (Gadavist) Injection and ProHance Injection. The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of gadobutrol when used for taking MR images of the brain and spine. The results of the MRI with gadobutrol Injection will be compared to the results of MR images taken without contrast and with the results of the MR images taken with ProHance.

Conditions

  • Diagnostic Imaging
  • Central Nervous System Diseases

Interventions

  • Gadobutrol (Gadavist, Gadovist, BAY86-4875)Drug

    Participants received a single dose of gadobutrol 0.1 mmol/kg body weight (bw) via i.v. (intravenous)

  • Gadoteridol (ProHance)Drug

    Participants received a single dose of gadoteridol at the approved dose, 0.1 mmol/kg bw, via i.v.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Combined Unenhanced/Gadobutrol-enhanced Magnetic Resonance Imaging (MRI) Compared to Unenhanced MRI by Blinded Reader 1 (BR1)Time frame: Up to 2 hours after injection of gadobutrol
  2. Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Combined Unenhanced/Gadobutrol-enhanced Magnetic Resonance Imaging (MRI) Compared to Unenhanced MRI by Blinded Reader 2 (BR2)Time frame: Up to 2 hours after injection of gadobutrol
  3. Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Combined Unenhanced/Gadobutrol-enhanced Magnetic Resonance Imaging (MRI) Compared to Unenhanced MRI by Blinded Reader 3 (BR3)Time frame: Up to 2 hours after injection of gadobutrol
  4. Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Combined Unenhanced/Gadobutrol-enhanced Magnetic Resonance Imaging (MRI) Compared to Unenhanced MRI by Average Reader (AR)Time frame: Up to 2 hours after injection of gadobutrol
  5. Number of Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Blinded ReadersTime frame: Up to 2 hours after injection of gadobutrol
  6. Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Normal Structures for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Blinded Reader 1 (BR1)Time frame: Up to 2 hours after injection of gadobutrol
  7. Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Normal Structures for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Blinded Reader 2 (BR2)Time frame: Up to 2 hours after injection of gadobutrol
  8. Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Normal Structures for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Blinded Reader 3 (BR3)Time frame: Up to 2 hours after injection of gadobutrol
  9. Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Normal Structures for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Average Reader (AR)Time frame: Up to 2 hours after injection of gadobutrol
  10. Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Blinded Reader 1 (BR1)Time frame: Up to 2 hours after injection of gadobutrol
  11. Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Blinded Reader 2 (BR2)Time frame: Up to 2 hours after injection of gadobutrol
  12. Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Blinded Reader 3 (BR3)Time frame: Up to 2 hours after injection of gadobutrol
  13. Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Average Reader (AR)Time frame: Up to 2 hours after injection of gadobutrol

Locations

79 sites in 8 countries. Site status is shown where the registry gives one.

  • West Alabama Research, Inc.

    Birmingham, Alabama

  • Achieve Clinical Research, LLC

    Tuscaloosa, Alabama

  • Los Gatos MRI

    Los Gatos, California

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California

  • Redwood Regional Medical Group, Inc.

    Santa Rosa, California

  • University of Florida - Jacksonville

    Jacksonville, Florida

  • NorthShore University HealthSystem-Evanston Hospital

    Evanston, Illinois

  • Atchison Hospital

    Atchison, Kansas

  • University of Maryland Hospital System

    Baltimore, Maryland

  • Johns Hopkins Hospital/Health System

    Baltimore, Maryland

  • Shields MRI - Brockton

    Brockton, Massachusetts

  • VA Boston Healthcare System-West Roxbury Division

    West Roxbury, Massachusetts

  • Washington University School of Medicine

    St Louis, Missouri

  • University of New Mexico School of Medicine

    Albuquerque, New Mexico

  • Kingston Neurological Associates, PC

    Kingston, New York

  • NYU Hospital for Joint Diseases

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • The Cleveland Clinic

    Cleveland, Ohio

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania

  • Allegheny General Hospital

    Pittsburgh, Pennsylvania

  • Rhode Island Hospital

    Providence, Rhode Island

  • Medical University of South Carolina

    Charleston, South Carolina

  • University of Washington Medical Center

    Seattle, Washington

  • Aurora Saint Luke's Medical Center

    Milwaukee, Wisconsin

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia

  • St George Hospital

    Kogarah, New South Wales, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Monash Medical Centre

    Clayton, Victoria, Australia

  • Landeskrankenhaus Donauregion Tulln

    Tulln, Lower Austria, Austria

  • Allgemeines Krankenhaus der Stadt Wien Universitätskliniken

    Vienna, State of Vienna, Austria

  • Medizinische Universität Graz

    Graz, Styria, Austria

  • LNK Wagner Jauregg

    Linz, Upper Austria, Austria

  • Centro de Diagnostico Medico

    Medellín, Colombia

  • Fundación Instituto de Alta tecnología médica de Antioquia

    Medellín, Antioquia, Colombia

  • Fundación Santa Fe de Bogotá - Hospital Universitario

    Bogotá, Cundinamarca, Colombia

  • DIME Clinica Neurocardiovascular S.A.

    Cali, Valle del Cauca Department, Colombia

  • Deutsches Krebsforschungszentrum

    Heidelberg, Baden-Wurttemberg, Germany

  • Städtisches Klinikum Karlsruhe gGmbH

    Karlsruhe, Baden-Wurttemberg, Germany

  • Klinikum Mannheim gGmbH

    Mannheim, Baden-Wurttemberg, Germany

  • Zentralklinikum Augsburg

    Augsburg, Bavaria, Germany

Showing 40 of 79 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.